CareDx Launches VANTx AI Solution for Advanced Transplant Data Analysis

CareDx Unveils VANTx: AI-Powered Platform for Transplant Data Analysis

CareDx (CDNA) has introduced VANTx, a cloud-based platform that leverages artificial intelligence to transform intricate transplant data into meaningful insights for clinical research and real-world evidence generation.

Jing Huang, CareDx’s Chief Data and AI Officer, presented VANTx at the Precision Medicine World Conference in Silicon Valley on March 5, 2026. Her session, “Transforming Transplant Care Through AI: From Predictive Insights to Precision Decisions,” was part of the conference’s focus on AI in clinical decision support.

The presentation showcased CareDx’s expertise in precision diagnostics and patient management for transplants, emphasizing how advanced AI—such as large language models—enables transplant centers to extract actionable information from complex datasets.

Impact on CDNA Stock Performance

Following the VANTx announcement, CareDx shares declined by 8.5%. However, over the past six months, CDNA stock has climbed 26.8%, outperforming the medical-dental supplies industry’s 2.9% growth and the S&P 500’s 4.1% increase.

The launch of VANTx marks a strategic move for CareDx, expanding its focus from diagnostics to comprehensive, data-driven transplant care. By harnessing proprietary datasets and AI analytics, CareDx enhances its value for transplant centers, researchers, and pharmaceutical collaborators. The platform’s ability to deliver measurable clinical and operational insights may also drive broader adoption of CareDx’s testing solutions.

Currently, CareDx’s market capitalization stands at $869.65 million.

Image Source: Zacks Investment Research

VANTx Platform: Features and Capabilities

VANTx is engineered for secure, scalable cohort analysis, allowing researchers to track patient data over time and assess treatment trends, outcomes, and clinical practices across transplant populations.

The platform supports transplant programs, clinicians, and pharmaceutical partners in hypothesis testing and evidence generation. By analyzing extensive datasets, VANTx informs treatment protocols, supports investigator-led studies, and aids in designing future clinical trials.

At its core, VANTx connects to CareDx’s growing repository of de-identified molecular and clinical trial data. The system can also incorporate additional data sources—such as electronic health records, quality metrics, and remote monitoring data—upon request, offering a holistic view of patient experiences and outcomes.

Built on a modern cloud infrastructure powered by Databricks, VANTx utilizes the Llama 3 foundation model and other machine learning techniques optimized for field-specific clinical data, enabling real-time processing of large-scale clinical and laboratory information.

VANTx integrates predictive and prognostic models from major transplant research initiatives, including KOAR, SHORE, ALAMO, and MAPLE. These models support research in kidney, heart, lung, and liver transplantation, and facilitate in-depth analysis of challenges like delayed graft function, microvascular inflammation, antibody-mediated rejection, cardiac allograft vasculopathy, and cancer risk.

Currently, VANTx is available to transplant centers through CareDx’s medical affairs team, with plans to launch a self-service, permission-based platform later in 2026, empowering clinicians to independently explore transplant data and insights.

Market Outlook for Transplant Diagnostics

According to Precedence Research, the global transplant diagnostics market is projected to reach $5.22 billion in 2026, with an expected compound annual growth rate of 6.5% through 2035.

Growth drivers include rising organ failure rates and increasing demand for advanced, non-invasive molecular testing and AI-powered compatibility tools that improve post-transplant survival.

Recent Developments at CareDx

• AlloHeme Validation: In February, CareDx shared clinical validation results for AlloHeme, a non-invasive test that detects relapse risks in patients with acute myeloid leukemia and myelodysplastic syndromes post-allogeneic hematopoietic cell transplantation. The test uses next-generation sequencing and AI to identify relapse signals in blood samples earlier than traditional methods.
• ImmuneScape Collaboration: In January, CareDx partnered with 10x Genomics to launch ImmuneScape, a multiomics research program aimed at advancing the understanding of transplant rejection and therapeutic response. Utilizing 10x’s Xenium spatial and Chromium Flex single-cell platforms, the initiative will generate high-resolution immune maps to better characterize antibody-mediated rejection and microvascular inflammation, guiding future diagnostic development.

CareDx, Inc. Stock Price

CareDx, Inc. price | CareDx, Inc. Quote

CDNA’s Zacks Rank and Top Medical Stock Picks

CareDx currently holds a Zacks Rank #3 (Hold).

Other notable stocks in the medical sector include:

• Intuitive Surgical (ISRG): Zacks Rank #1 (Strong Buy). Reported Q4 2025 adjusted EPS of $2.53, exceeding estimates by 12.4%, with revenues of $2.87 billion (4.7% above consensus). Estimated long-term earnings growth is 15.7%, outpacing the industry’s 13.6%. The company has beaten earnings estimates in the last four quarters, with an average surprise of 13.2%.
• Phibro Animal Health (PAHC): Zacks Rank #1. Delivered Q2 fiscal 2026 adjusted EPS of $0.87, surpassing estimates by 27.1%, and revenues of $373.9 million (4.7% above consensus). Long-term earnings growth is projected at 21.5%, compared to the industry’s 12.2%. The company has exceeded earnings expectations in the past four quarters, with an average surprise of 20.1%.
• Cardinal Health (CAH): Zacks Rank #2 (Buy). Reported Q2 fiscal 2026 adjusted EPS of $2.63, 10% above estimates, with revenues of $65.6 billion (0.9% above consensus). Long-term earnings growth is estimated at 15%, compared to the industry’s 9.2%. The company has beaten earnings estimates in the last four quarters, with an average surprise of 9.3%.

For a full list of Zacks #1 Rank stocks, click here.

Spotlight: Top Semiconductor Stock

A lesser-known company specializing in semiconductor products—unlike industry giants such as NVIDIA—is poised to benefit from the next wave of market expansion. With robust earnings growth and a growing customer base, this company is well-positioned to meet surging demand for AI, machine learning, and IoT. Global semiconductor manufacturing is expected to soar from $452 billion in 2021 to $971 billion by 2028.

Get the Latest Stock Recommendations

Looking for the latest picks from Zacks Investment Research? Download the 7 Best Stocks for the Next 30 Days here.

Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report

Cardinal Health, Inc. (CAH): Free Stock Analysis Report

Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report

CareDx, Inc. (CDNA): Free Stock Analysis Report

Original article published by Zacks Investment Research

Zacks Investment Research